AstraZeneca Criticizes HHS For Bid To Skirt Drug Price Suit
Government Contracts
DECEMBER 4, 2023
AstraZeneca has chided the federal government for seeking a quick win against the drugmaker's challenge to the Medicare drug price negotiation program in a recent brief, arguing that the Centers for Medicare and Medicaid Services mistakenly believes it has "absolute authority to unilaterally dictate prices."
Let's personalize your content